Cetuximab disappoints in colon cancer
9 June 2010
| by Nicola Garrett
The addition of cetuximab to standard adjuvant chemotherapy with FOLFOX does not extend disease free survival or overall survival for patients with stage III colon cancer with wild-type KRAS, a phase III study finds....
Want to read complete article? Please Sign in or Register.